Infantile hemangiomas are localized and rapidly growing regions of disorganized angiogenesis. We show that expression of vascular endothelial growth factor receptor-1 (VEGFR1) in hemangioma endothelial cells (hemECs) and hemangioma tissue is markedly reduced compared to controls. Low VEGFR1 expression in hemECs results in VEGF-dependent activation of VEGFR2 and downstream signaling pathways. In hemECs, transcription of the gene encoding VEGFR1 (FLT1) is dependent on nuclear factor of activated T cells (NFAT). Low VEGFR1 expression in hemECs is caused by reduced activity of a pathway involving b1 integrin, the integrin-like receptor tumor endothelial marker-8 (TEM8), VEGFR2 and NFAT. In a subset of individuals with hemangioma, we found missense mutations in the genes encoding VEGFR2 (KDR) and TEM8 (ANTXR1). These mutations result in increased interactions among VEGFR2, TEM8 and b1 integrin proteins and in inhibition of integrin activity. Normalization of the constitutive VEGFR2 signaling in hemECs with soluble VEGFR1 or antibodies that neutralize VEGF or stimulate b1 integrin suggests that local administration of these or similar agents may be effective in hemangioma treatment.
Infantile hemangiomas, localized lesions of disorganized angiogenesis, are the most common tumors of infancy 1 . They typically appear around the second week of life, proliferate over the course of 6-10 months and involute over the following 7-10 years [1] [2] [3] . HemECs within the lesions show X chromosome inactivation patterns indicative of a clonal origin and a characteristic expression pattern 1, [4] [5] [6] that is stably maintained in cultured hemECs and that differs from that of other endothelial cell types, including human dermal microvascular endothelial cells (HDMECs). It has been proposed that hemECs are either differentiated toward the placental microvascular phenotype or originate from placental endothelial cells 7, 8 . Additionally, epidemiological studies and rare familial cases suggest a genetic influence 9, 10 .
We report here that cultured hemECs from nine unrelated individuals with hemangioma are characterized by constitutively active VEGFR2 signaling, associated with low expression of FLT1. The VEGFR1 receptor is known to bind VEGF with high affinity and thereby prevent VEGF from activating VEGFR2 and its downstream targets 11, 12 . In a screen of candidate genes in these individuals for potential disease-associated mutations, we found germline heterozygosity for missense mutations in the gene encoding the integrin-like receptor TEM8 13, 14 in one individual and in the gene encoding VEGFR2 in two others. Investigation of the impact of these mutations elucidated a pathway controlling FLT1 transcription that involves TEM8, VEGFR2, b1 integrin and NFAT. The mutations identified in TEM8 or VEGFR2 inhibit the activity of this pathway. Although these mutations were not found in all nine individuals, hemECs from all of these individuals showed reduced NFAT activity and VEGFR1 expression.
RESULTS

VEGFR2-dependent signaling is upregulated in hemECs
In initial experiments, we compared the amount of VEGFR2 phosphorylation between HDMEC and hemEC primary cultures. Primary cells from nine individuals with hemangioma were characterized; data on eight of these individuals (all the females) were reported in a previous publication 1 Table 1 online). Phosphorylation of VEGFR2 at residue Tyr1175 was at very low levels in lysates of HDMECs cultured without exogenous VEGF but at high levels in lysates from hemECs (Fig. 1a) . Addition of VEGF-specific neutralizing antibodies to the cultures reduced levels of phosphorylated VEGFR2 (phospho-VEGFR2; Fig. 1a ). Using phosphopeptide arrays to assess kinase activities, we observed increased activity of kinases in hemEC lysates, reflected by increased phosphorylation of VEGFR2 peptides and of peptides representing multiple downstream targets ( Table 1) . Phosphorylation patterns in hemECs were very similar to those of HDMECs treated with VEGF, consistent with activation of VEGFR2 signaling pathways ( Table 1) . Phosphorylation of peptides representing epidermal growth factor and fibroblast growth factor receptors was at background levels in all lysates (Supplementary Table 2 online).
(Supplementary
Quantitative measurement of VEGFR2 protein abundance by ELISA showed that it was slightly lower in hemECs compared to HDMECs ( Supplementary Fig. 1 online) . Quantitative multiplex ELISAs confirmed high phosphorylation levels of the VEGFR2 targets ERK and Akt in hemEC lysates (Fig. 1b) and showed increased protein expression of several downstream targets of VEGFR2 signaling. For example, endogenous VEGF and GLUT-1 glucose transporter protein expression was as high in unstimulated hemECs as in VEGFstimulated HDMECs (Fig. 1b) . The migratory and proliferative activities of hemECs were almost identical to those of VEGFstimulated HDMECs (Fig. 1c,d) . Treatment with the soluble form of VEGFR1 (sR1) or with small interfering RNA (siRNA) to silence VEGFR2 ( Supplementary Fig. 1 ) strongly inhibited these activities (Fig. 1c,d) . The results suggest that increased VEGFR2 phosphorylation in hemECs depends on VEGF binding at the cell surface.
Reduced VEGFR1 expression and NFAT activation in hemECs Increased VEGF activity at the cell surface raised the possibility that expression of the VEGF decoy receptor VEGFR1 may be reduced in hemECs. Using ELISA to determine the abundance of VEGFR1 protein in several types of control cells and in hemECs from all nine subjects with hemangioma, we found that VEGFR1 expression in hemECs was only 10-20% of that in control cells (Fig. 2a) . Experiments using RT-PCR that can distinguish between the membrane-bound VEGFR1 (mR1) and soluble VEGFR1 isoforms 15 showed that transcript levels of both isoforms were reduced in hemECs compared to HDMECs (data not shown). Stable overexpression of mR1 in hemECs lowered phospho-VEGFR2 and phospho-ERK levels (Fig. 2b) . Overexpression of a kinase-dead mutant, mut-mR1 (ref. 16) , had the same effect as mR1 (Fig. 2b) . Overexpression of a mutant VEGFR1 lacking the extracellular domain had no effect (data not shown). We therefore concluded that reduced expression of VEGFR1, combined with increased levels of endogenous VEGF (Fig. 1b) , maintains increased VEGFR2 activation and signaling in hemECs.
Low VEGFR1 transcript and protein levels in all the hemECs tested led us to sequence 1 kb of the FLT1 promoter in hemEC DNA from all nine subjects. Finding no sequence changes, we asked how FLT1 is transcriptionally regulated in endothelial cells. We identified a potential NFAT binding site (GGACCCT) upstream of the transcriptional start site (at base pairs -83 to -89), next to an AP-1 binding site, in a region of the FLT1 promoter reported to contain a transcriptional activator site 17 . Replacement of GGA (at base pairs -87 to -89) with TCA in a luciferase-containing reporter essentially eliminated luciferase activity in HDMECs (Fig. 2c) . In contrast, replacement of GGA with TCA at a site downstream of the AP-1 binding site (base pairs -65 to -67) had no effect on activation of the reporter (data not shown). A double-stranded oligonucleotide containing the wild-type GGA sequence at base pairs -87 to -89 had substantial binding activity for NFATc1 (NFAT2; data not shown) and NFATc2 (NFAT1; Fig. 2c ). In contrast, an oligonucleotide containing TCA had no NFAT binding activity (Fig. 2c) . Overexpression of a constitutively active form of NFATc1 stimulated VEGFR1 protein expression in both HDMECs and hemECs ( Supplementary Fig. 2 online) . These results indicated that NFAT transcription factors are activators of the FLT1 promoter and suggested that NFAT activity is low in hemECs. Figure 1 VEGFR2-dependent signal transduction is upregulated in hemECs. (a) Immunoblots of cell lysates with antibodies against phospho-VEGFR2 Tyr1175 (P-R2) and VEGFR2 (R2). HDMEC and hemEC were serum-starved overnight and treated with 2 mg ml -1 VEGF neutralizing antibody (VEGF Ab; + lanes) or control mouse IgG (-lanes) for 48 h before lysis. (b) Quantitative multiplex ELISA for targets of VEGFR2 signaling. Data were normalized by dividing experimental values by a-tubulin values. HDMECs and hemEC cultures from subjects 2, 4 and 21A were treated with control siRNA and vehicle (PBS + 0.1% BSA; control), with VEGFR2-specific siRNA (R2 siRNA), with 25 ng ml -1 VEGF for 15 min (to measure ERK1/2 or Akt protein phosphorylation; VEGF) or 12 h (to measure VEGF or GLUT-1 protein expression; VEGF), with a combination of VEGFR2-specific siRNA and 25 ng ml -1 VEGF for 15 min (to measure ERK1/2 or Akt protein phosphorylation; VEGF + R2 siRNA) or 12 h (to measure VEGF or GLUT-1 protein expression; VEGF + R2 siRNA), or with 50 ng ml À1 recombinant sVEGFR1 (sR1). Data represent means ± s. NFAT is activated by the Ca 2+ -and calmodulin-dependent phosphatase calcineurin 18 and is a target of VEGFR2 signaling in endothelial cells. Because VEGFR2 signaling is upregulated in hemECs, the evidence suggesting reduced NFAT activity was unexpected. Therefore, we measured transcript levels of other NFAT-regulated genes. The results showed that transcripts for several such genes, including genes encoding Down syndrome critical region protein-1 (also known as modulatory calcineurin-interacting protein-1; RCAN1), monocyte chemotactic protein-1 (CCL2) and cyclooxygenase-2 (PTGS2) [19] [20] [21] , were substantially reduced in hemECs compared with HDMECs (Fig. 2d) . This indicates low basal NFAT activity in hemECs. Transcript levels of NFAT1 and NFAT2 were not different between HDMECs and hemECs (Fig. 2d) . As assessed by real-time PCR, PTGS2/KDR and FLT1/KDR transcript ratios were considerably lower in proliferating hemangioma tissue and hemECs than in HDMECs or other control endothelial cells, or in involuting hemangioma tissue or control tissues (Fig. 2e) . Incubation of HDMECs with a cell-permeable inhibitor of the NFAT-calcineurin interaction decreased FLT1 transcript levels and increased VEGFR2 and ERK phosphorylation levels in a dose-dependent manner (Fig. 2f) , showing that NFAT inactivation is indeed associated with the hemangioma VEGFR2 pathway activation through VEGFR1 downregulation. A low level of NFAT activation in hemECs was indicated by antibody staining for NFATc2 showing considerably less nuclear staining in hemECs than in HDMECs after stimulation with VEGF or ionomycin (Supplementary Fig. 3a online) . Preliminary experiments showed that ionomycin-stimulated release of Ca 2+ from intracellular stores was reduced in hemECs compared to HDMECs (Supplementary Fig. 3b ).
Reduced b1 integrin activity in hemECs The key role of Ca 2+ in NFAT activation and preliminary evidence that Ca 2+ release in hemECs may be abnormal led us to examine the activation state of integrin receptors in hemECs. A link between integrins and Ca 2+ signaling is well established. For example, treatment with integrin-specific stimulatory antibody increases Ca 2+ levels in endothelial cells [22] [23] [24] , and integrin-mediated cell adhesion can trigger calcium influx 25, 26 .
Because several integrins expressed by endothelial cells contain the b1 integrin subunit, we treated HDMECs or hemECs with b1 integrin-specific stimulatory antibody. This increased association of NFATc2 with the FLT1 promoter in chromatin immunoprecipitates (Fig. 3a) and induced an increase in the transcript levels of FLT1 and PTGS2 in both HDMECs and hemECs (Fig. 3b) . In hemECs, treatment with this antibody resulted in increased VEGFR1 expression and was associated with reduced VEGFR2 phosphorylation (Supplementary Fig. 4 online) . To determine whether the differences between HDMECs and hemECs in VEGFR1 protein expression can be explained by differences in b1 integrin activity, we compared integrin functions in HDMECs and hemECs. Staining of cell cultures with antibody to total b1 integrin showed no difference (Fig. 3c) . However, immunostaining with an antibody that recognizes only active b1 integrin (HUTS-21) 27 showed markedly decreased reactivity at the cell surface of hemECs from subject 2 compared with HDMECs (Fig. 3c) ; similar results were obtained with hemECs from subjects 4 and 21A (data not shown). Consistent with decreased b1 integrin activity on the surface of hemECs, we found that adhesion of hemECs to type I collagen or fibronectin was substantially lower than that of HDMECs, but no differences were seen on vitronectin, a protein that binds b3-containing integrins ( Supplementary Fig. 5 online) . Moreover, hemECs and HDMECs grown in suspension cultures in the absence of fibronectin had only minimal differences in the levels of expression of the protein products of NFAT-regulated genes (FLT1 and PTGS2); however, in the presence of fibronectin these levels were increased in HDMECs but not in hemECs (data not shown). Finally, phosphorylation of Tyr397 in focal adhesion kinase, an indicator of integrin activation [28] [29] [30] , was significantly reduced in hemECs from all nine subjects compared to HDMECs or human umbilical vein endothelial cells (HUVECs; data not shown). These results indicate that low levels of b1 integrin activity, a characteristic feature of all of the hemEC cultures that we have examined, may provide an explanation for the reduced activation of NFAT and low level of VEGFR1 expression.
TEM8 and VEGFR2 mutations affect VEGFR1 expression
In light of evidence for a genetic component to hemangioma formation 9,10,31 , we asked whether suppressed NFAT activation and low VEGFR1 expression in hemECs could result from germline or somatic mutations. Using a candidate gene approach, we sequenced the complete coding sequences of 24 genes using DNA from the nine hemEC cultures, and confirmed the results using genomic DNA isolated from the blood of the relevant subjects. These candidate genes were selected because of their roles in controlling endothelial cell proliferation, migration and adhesion to extracellular matrix or controlling hypoxia-inducible factor-1, a key transcription factor for regulating VEGF expression. In addition to neutral and common polymorphisms, we found heterozygosity for nucleotide changes resulting in potential disease-associated amino acid substitutions in three of the nine individuals with hemangioma (Supplementary Tables 1 and 3 online).
In hemECs from subject 4, we found a germline G-A transition that replaces alanine with threonine in the transmembrane domain of the integrin-like molecule TEM8 (referred to as EC4 TEM8-A326T hemECs below; Fig. 4a ). Using allele-specific PCR, we screened for the mutant allele in blood genomic DNA samples collected from 110 individuals with a history of hemangioma and 295 controls (all people of European descent). No other individual carrying the mutant allele was found.
ANTXR1 is expressed as three alternatively spliced transcripts (variants 1, 2 and 3) 13 (Fig. 4a) . Cell culture 
2,000 stimulated VEGFR1 protein expression without affecting the low levels of phospho-VEGFR2 and phospho-ERK (Fig. 4b) . Overexpression of HA-tagged mutant TEM8 variant 1 or TEM8 variant 3 (lacking the cytoplasmic and transmembrane domains) reduced VEGFR1 expression and increased phospho-VEGFR2 and phospho-ERK abundance (Fig. 4b) . Overexpression of wild-type TEM8 variant 1 in hemECs from subjects 2 and 21A as well as in EC4 TEM8-A326T hemECs increased VEGFR1 expression and reduced phospho-VEGFR2 and phospho-ERK levels (Fig. 4c) .
In hemECs from subjects 2 and 17B, we found a T-C germline transition that replaces cysteine with arginine at position 482 in the immunoglobulin-like domain V of the VEGFR2 extracellular region (referred to as EC2 VEGFR2-C482R and EC17B VEGFR2-C482R hemECs below; Fig. 4d ). Allele-specific PCR identified heterozygosity for the same change in eight blood genomic DNA samples collected from an additional 105 individuals with a history of hemangioma (for a total detection rate of 10 out of 114 individuals with a history of hemangioma) and in 12 DNA samples from 295 controls (all people of European descent), which include individuals with hemangioma at the population frequency (10%; see Methods). Assuming that 10% of the individuals in the control group had a history of hemangioma, the difference in the frequency of the C482R change between individuals with a history of hemangioma and individuals with no such history is statistically significant (P ¼ 0.02, Fisher's exact two-tailed test). No difference in VEGFR2 receptor expression and VEGFinduced VEGFR2 phosphorylation was apparent between 293-EBNA cells in which either wild-type or C482R-mutant receptor was transiently expressed (data not shown), consistent with the fact that the mutation is located outside the VEGF-binding region 32 .
Retroviral overexpression of His-tagged wild-type VEGFR2 in HDMECs resulted in increased VEGFR1 expression, but no significant changes in phospho-VEGFR2 and phospho-ERK abundance (Fig. 4e) . Unlike overexpression of mutant TEM8, overexpression of His-tagged C482R-mutant VEGFR2 in HDMECs lowered VEGFR1 protein expression only slightly (Fig. 4e) . Overexpression of wild-type VEGFR2 in EC4 TEM8-A326T , EC2 VEGFR2-C482R , EC17B VEGFR2-C482R hemECs or hemECs from subject 21A increased VEGFR1 protein expression and reduced phospho-VEGFR2 and phospho-ERK abundance (Fig. 4f) . To determine whether this stimulatory effect requires signaling through the VEGFR2 kinase domain, we used retroviral transfection to stably express various VEGFR2 expression constructs in EC2 VEGFR2-C482R hemECs (Fig. 4g) . Truncation of the cytoplasmic domain or replacement of three of the tyrosine residues (that are necessary for kinase activity) within the cytoplasmic domain with phenylalanines did not compromise the ability of VEGFR2 to stimulate VEGFR1 expression (Fig. 4g) . Mutation of the Cys482 codon to a serine codon also did not affect the ability of VEGFR2 to stimulate VEGFR1 expression (Fig. 4g) . Finally, a Q472H substitution, reported as a potential hemangioma mutation in VEGFR2 (ref. 4) , did not affect stimulation of VEGFR1 expression (Fig. 4g) . This is consistent with our finding that the Q472H KDR allele is common (27%) among control chromosomes (data not shown). Similar results were obtained when the VEGFR2 expression constructs were transfected into EC4 TEM8-A326T hemECs or hemECs from subject 21A (data not shown).
We conclude, therefore, that the effect seen with the C482R mutation of VEGFR2 on VEGFR1 expression is specific to that particular amino acid substitution and that sequences within the extracellular immunoglobulin-like domain V of VEGFR2 (and not the kinase domain) are crucial for the ability of VEGFR2 to stimulate VEGFR1 expression.
Abnormal interactions among VEGFR2, TEM8 and b1 integrin The amounts of b1 integrin and TEM8 were almost the same in lysates of hemECs and control cells (Fig. 5a) . However, immune complexes generated with antibody to VEGFR2 from hemEC lysates contained substantially higher amounts of b1 integrin and TEM8 than did complexes from HDMEC or HUVEC lysates (Fig. 5a) . Similar results were obtained in reciprocal immunoprecipitation assays with antibody to TEM8 (data not shown).
To determine whether the C482R mutation in VEGFR2 and the A326T mutation in TEM8 affect the recruitment of the proteins into immune complexes with b1 integrin, we expressed mutant and wildtype receptors in 293-EBNA cells, as these cells express b1 integrin but neither VEGFR2 nor TEM8 14, [33] [34] [35] . Western blotting of immunoprecipitates generated with antibody to VEGFR2 showed that the mutations enhanced recruitment of the proteins into a complex with b1 integrin (Fig. 5b) , suggesting that the mutations increase the affinity of VEGFR2 and TEM8 for each other, b1 integrin or another common partner within the complex. Similar results were obtained in reciprocal immunoprecipitation assays with antibody to TEM8 (data not shown).
Treatment of HDMECs with siRNA for ANTXR1, KDR or NFAT1 blocked the stimulatory effect on FLT1 expression by b1 integrinspecific stimulatory antibody or VEGF (Fig. 5c) . These data indicate that TEM8, VEGFR2 and b1 integrin functionally interact to control FLT1 expression in an NFAT-dependent manner in endothelial cells. This interaction, and, consequently, regulation of VEGFR1 expression, is compromised in hemECs. Next, we examined the effects of expressing A326T-mutant TEM8 or C482R-mutant VEGFR2 in HDMECs and wild-type TEM8 or wildtype VEGFR2 in hemECs. Expression of mutant TEM8 substantially reduced association of NFATc2 with the VEGFR1 promoter in HDMECs; expression of wild-type TEM8 or wild-type VEGFR2 in EC4 TEM8-A326T hemECs increased the association (Fig. 5d) . Overexpression of mutant TEM8 in HDMECs substantially reduced the amount of active b1 integrin, as assessed by staining with HUTS-21 antibody (Fig. 3c) . In contrast, overexpression of mutant VEGFR2 in HDMECs reduced the amount of active b1 integrin only slightly (Fig. 4e) . Overexpression of wild-type VEGFR2 or TEM8 in hemECs increased HUTS-21 staining (Fig. 3c) . Finally, stable overexpression of mutant TEM8 in HDMECs stimulated BrdU incorporation and migration to levels approaching those of EC4 TEM8-A326T hemECs (Fig. 5e) . These results correlate well with changes in VEGFR1 expression in HDMECs or hemECs transfected with wild-type or mutant TEM8 or mutant VEGFR2 (Fig. 4) .
DISCUSSION
We showed that FLT1 is an NFAT target gene in endothelial cells and that NFAT target genes are downregulated in all nine hemEC cultures that we studied (Fig. 5f) . As a consequence of reduced VEGFR1 decoy function, VEGFR2 and its downstream targets are activated in a VEGFdependent manner, and the protein expression of downstream targets, such as VEGF and GLUT-1, are increased. Proliferation and migration of hemECs are also upregulated. In addition, reduced NFAT activation in hemECs is associated with low activity of b1 integrin. Finally, we found increased interactions among b1 integrin, the integrin-like receptor TEM8 and VEGFR2 in all nine hemEC cultures. The only differences we found among the nine hemEC cultures are that missense mutations in the genes encoding TEM8 and VEGFR2 are present in hemECs from three of the nine subjects. Both mutations identified have a marked effect on the amount of TEM8 and b1 integrin in immune complexes with VEGFR2 when the proteins are expressed in 293-EBNA cells, similar to what is seen with lysates from all hemEC cultures. On this basis, we suggest that hemECs have a low 'setpoint' of integrin-NFAT activation as a consequence of the formation of an abnormal complex including VEGFR2, TEM8 and b1 integrin (Fig. 5f) .
In hemECs, increased complex formation is associated with a smaller amount of active b1 integrin at the cell surface, suggesting that b1 integrin (and possibly other integrins) are in the closed, lowaffinity conformation or are somehow blocked. Thus, decreased integrin-NFAT activation and VEGFR1 expression in EC2 VEGFR2-C482R , EC4 TEM8-A326T and EC17B VEGFR2-C482R hemECs may be caused by inhibition of integrin activation within the TEM8-and VEGFR2-containing complex. Determining the detailed mechanistic steps in the integrin-NFAT pathway will require further studies. However, on the basis of what is currently known about NFAT activation mechanisms, integrins may control processes related to dephosphorylation of inactive NFAT in the cytoplasm and nuclear import of active NFAT.
In the candidate genes that we sequenced, no mutations have been found in six of the hemEC cultures (for example, that from subject 21A). However, overexpression of wild-type VEGFR2 or TEM8 normalizes VEGFR1 expression and VEGFR2 phosphorylation not only in hemEC cultures containing mutations in the genes encoding TEM8 and VEGFR2, but also in those not containing such mutations, such as in hemECs from subject 21A. This suggests that hemangioma formation in the six individuals in whom we have not yet found mutations may be associated with mutations in genes encoding other pathway components upstream of NFAT or perhaps other cell surface or cytoplasmic proteins that interact with integrins, TEM8 or VEGFR2. Thus, identifying other components of the complex may provide good candidates for future mutation screens.
In the mechanistic model proposed here for hemangioma endothelial dysfunction, both VEGFR2 and TEM8 mutations have effects on integrin-NFAT activation. However, the two mutations differ in their ability to induce the hemEC phenotype when the mutant proteins are stably expressed in HDMECs. Overexpression of mutant TEM8 in HDMECs reduces active b1 integrin on the cell surface, decreases the association between NFAT and the VEGFR1 promoter and decreases VEGFR1 expression, indicating that the effect of the mutation is based on a dominant-negative mechanism. The similarity between the consequences of overexpressing full-length A326T-mutant TEM8 and TEM8 variant 3 (lacking the transmembrane and cytoplasmic domains) in HDMECs suggests that the cytoplasmic domain of TEM8 is required for its ability to positively control integrin-NFAT activation and VEGFR1 expression. Moreover, many types of mutations in ANTXR1, even in introns, could have similar effects, suggesting that sequencing of the entire ANTXR1 gene (including introns) in additional hemangioma DNA samples may be illuminating.
Overexpression of the C482R-mutant VEGFR2 in HDMECs decreased VEGFR1 expression and b1 integrin activity only slightly.
However, overexpression of wild-type VEGFR2 in hemECs normalized the amount of active integrin detected with the HUTS-21 antibody, increased the association between NFATc2 and the FLT1 promoter and increased VEGFR1 expression. In contrast, overexpression of C482R-mutant VEGFR2 in hemECs had no effect on VEGFR1 expression. These results suggest that the C482R mutation in VEGFR2 is a loss-offunction mutation in the context of the ability of VEGFR2 to affect VEGFR1 expression.
Considering all of these data together, we conclude that the mutations in the genes encoding TEM8 and VEGFR2 that we identified represent risk-factor mutations for infantile hemangioma. Both sequence changes affect highly conserved amino acid residues. These heterozygous germline missense changes in KDR and ANTXR1 do not appear to cause systemic vascular abnormalities in the individuals who carry them. In that sense, they seem similar to germline mutations in other genes that cause localized vascular lesions. Familial venous and glomuvenous malformations are caused by heterozygous germline mutations in the genes encoding the endothelial tyrosine kinase receptor TIE2 and the vascular smooth muscle cytoplasmic protein glomulin, respectively. Recent evidence suggests that these heterozygous germline mutations are not sufficient to cause the localized lesions of abnormal veins and that they require somatic mutations in the wild-type alleles of the same genes (encoding TIE2 or glomulin) for lesions to form 36, 37 . Because the nine different hemEC cultures that we have analyzed in this study show clonality 1 , the germline mutations in EC2 VEGFR2-C482R , EC4 TEM8-A326T and EC17B VEGFR2-C482R hemECs are probably associated with a secondary somatic event that triggers the expansion of endothelial cells within the lesions. To account for the difference in progression between hemangiomas (which undergo age-dependent involution) and venous or glomuvenous malformations (which do not), we speculate that this secondary lesion-triggering event in an individual carrying a germline risk mutation for hemangioma may be a physiological event (for example, emboli of placental cells or perinatal hypoxia 38, 39 ) rather than a somatic mutation.
It is well known that when cells are propagated in vitro their behavior can differ from that in vivo. Therefore, a key question is whether differences between several types of control cells and hemECs in vitro truly reflect in vivo differences between normal microvascular endothelial cells and endothelial cells within proliferating hemangiomas. Several findings indicate that the signaling abnormalities of cultured hemECs are indeed those of the tumor cells in vivo. First, FLT1/KDR and PTGS2/KDR transcript ratios are markedly lower in proliferating hemangioma tissue than in control tissues and involuting hemangiomas, and similar marked differences in these ratios are seen between cultured hemECs and control endothelial cells. Second, increased GLUT-1 and VEGF protein expression in hemECs reflects increased GLUT-1 and VEGF expression in hemangioma tissue 5, 40 . Third, increased proliferation of hemECs in vitro matches increased proliferation in vivo 41 . Therefore, the mechanistic model for hemangioma dysfunction, based on studies of hemECs in vitro, should be applicable to the proliferating tumor. On the basis of this model, we suggest that locally administered antibodies to VEGF, inhibitors of VEGFR2 tyrosine kinase or other agents affecting components of the VEGFR2, TEM8, b1 integrin and NFAT signaling pathway could be effective in treating rapidly growing hemangiomas.
METHODS
Plasmids. The constitutively active form of NFATc1 has been previously described 37 . The construct containing the FLT1 promoter linked to luciferase has also been previously described 42 . We obtained full-length human FLT1 complementary DNA (cDNA) inserted into a pcDNA3.1 vector 43 . Full-length human KDR cDNA in pcDNA3.1/Myc-His(+)B and human cDNA in pcDNA3 encoding VEGFR1 with a Y1213F mutation have been previously described 16, 44 . We tagged VEGFR2 with a His epitope by PCR. Full-length human cDNAs encoding TEM8 with an HA tag or TEM8 variant 3 and cloned into pIREShyg2 have been previously described 45 . We amplified the cDNA fragments by PCR and cloned them into the bicistronic retroviral vector pMXs 46 . We introduced point mutations with the QuickChange site-directed mutagenesis kit (Stratagene) and verified them by sequencing.
Isolation of endothelial cells, cell culture and study subject material. We established primary cultures of hemECs from nine subjects of European descent-all females, except subject 2. All, except two (subjects 17 and 21), had single lesions (Supplementary Table 1 ). We selected these hemECs for the studies because they are derived from typical proliferating hemangioma 6 and show clonality 1 , and cryopreserved cells at low population doublings (3-5) are available. All of the properties that we examined remained constant over several cell passages (5-15) in culture.
We obtained age-matched neonatal foreskin-derived HDMECs and normal human female skin endothelial cells (HFSECs) isolated from the face of age-matched female infants using methods identical to those described previously 1 . We isolated cord blood endothelial progenitor cells (cbEPCs) as described previously 47 . Briefly, in the case of HDMECs, HFSECs and hemECs, we digested tissue samples with trypsin, resuspended the cells in EBM (Clonetics CC-3121) supplemented with 20% heat-inactivated FBS (Hyclone), 2 mM glutamine, 100 U ml -1 penicillin, 100 mg ml -1 streptomycin (Irvine Scientific), 0.25 mg ml -1 amphotericin B (GIBCO-BRL), 0.5 mM N-6,2¢-Odibutyryladenosine 3¢:5¢-cyclic monophosphate (Sigma) and 1.0 mg ml -1 hydrocortisone (Sigma) as previously described 1 and grew them to preconfluence (5-7 d). We purified the endothelial cells from these primary cultures with Ulex europaeus I lectin-coated magnetic beads 1 . In the case of cbEPCs, we isolated mononuclear cells by Ficoll-Hypaque density gradient sedimentation, plated them on attachment factor-coated dishes (Cascade Biologics) in EBM-2 medium (Clonetics CC-3156) supplemented with EGM-2 SingleQuots (Clonetics CC-4176) (except hydrocortisone), 1Â glutamine-penicillinstreptomycin (GIBCO-BRL), 20% heat-inactivated FBS (Hyclone) and 15% human plasma and selected the cells with magnetic beads conjugated to antibody to CD34 and antibody to CD133 (ref. 47) . We purchased HUVECs from Clonetics. We tested all HDMEC cultures for the presence of transcripts of the lymphatic endothelial marker PROX1 by PCR and found them to be negative.
We grew all of the different endothelial cell types on AF-coated dishes (Cascade Biologics) in EBM-2 medium (Clonetics CC-3156) supplemented with EGM-2 SingleQuots (Clonetics CC-4176), 20% heat-inactivated FBS (Hyclone) and 1Â antibiotic-antimycotic (GIBCO-BRL) in 5% CO 2 at 37 1C. We grew 293-EBNA cells (Invitrogen) following the manufacturer's recommendations. Before some experiments, we cultured endothelial or 293-EBNA cells in the absence of serum and supplemental growth factors for 12-24 h. In experiments involving siRNA treatment to reduce levels of transcripts for KDR, ANTXR1 and NFAT1, we performed control experiments to ensure that levels of transcripts for the silenced genes were reduced by 480% (see Supplementary Fig. 1 ). Control samples not treated with specific siRNA were treated with control siRNA.
To allow comparisons to be made between tissues and cultured endothelial cells, we chose to compare the FLT1 and PTGS2 transcript levels relative to KDR (with the assumption that the two VEGF receptors are endothelial cell specific 48 ). Thus, this ratio provides information about endothelial cell-specific properties in different tissues and in cultures of endothelial cells where the proportions of endothelial cells vary substantially.
To determine FLT1 promoter activity in HDMECs and hemECs, we transfected the FLT1 promoter-luciferase reporter into cells. To examine the effects of the VEGFR2 and TEM8 mutations on the ability of the proteins to form a complex with b1 integrin, we stably transfected 293-EBNA cells with constructs encoding WT or mutant VEGFR2 (His-tagged; in the puromycin-resistant pMXs vector) and TEM8 (HA-tagged; in the hygromycin B resistant pIREShyg2 vector). We selected transfected cells for both puromycin (10 mg ml -1 ) and hygromycin B (300 mg ml -1 ) resistance.
To determine whether inhibition of NFAT activation in control endothelial cells affected VEGFR1 expression and VEGFR2 activation, we incubated HDMECs with different concentrations of the cell-permeable NFAT inhibitor III (INCA-6; Calbiochem) for 12 h. We analyzed lysates by real-time PCR for FLT1 transcripts and by immunoblotting.
We obtained six resected infantile hemangioma specimens (hem75, hem76, hem82, I-39, I-47 and I-52) for extraction of RNA. We obtained tissues from full-term placenta and foreskin as previously described 48 . We extracted blood-derived genomic DNA from 105 unrelated individuals of European descent with a history of hemangioma and 295 control subjects with the Puregene DNA purification kit (Gentra Systems). These control subjects include individuals with hemangioma at the population frequency (10%); infants are not screened for the absence of hemangioma and it is therefore not possible to find individuals with a documented history of a hemangioma-free childhood. Collection and handling of all human material was done according to the guidelines of Harvard Medical School Committee on Human Studies and the Children's Hospital Boston, Committee on Clinical Investigation for protection of research subjects, and informed consent was obtained from all subjects.
Chromatin immunoprecipitation. We analyzed the interaction of NFATc2 with the FLT1 promoter in vivo with ChIP-IT (Active Motif) according to the methods recommended by the manufacturer. Instead of sonicating, we sheared cellular DNA with an Enzymatic Shearing Kit (Active Motif) for 10 min. We immunoprecipitated the chromatin (input DNA) with 5 mg of NFATc2-specific antibody (Santa Cruz sc-7295X) or control mouse IgG. We amplified the DNA purified from immunoprecipitates by PCR with human FLT1 promoterspecific primers: 5¢-CTGGGAGGAAGAAGAGGGTAGGTG-3¢ and 5¢-CGA GGGCGGGGGCGATTTAT-3¢. These primers amplify a 124-base pair fragment containing the putative NFAT-binding site of interest. PCR conditions were as follows: 95 1C for 15 min, followed by denaturation for 30 s at 95 1C, annealing for 30 s at 60 1C and extension for 30 s at 72 1C. We analyzed the amplified DNA products by quantitative real-time PCR as described above and resolved them by agarose gel electrophoresis.
Quantitative protein analysis. We measured the abundance of VEGFR1 and VEGFR2 with a specific ELISA kit (R&D Systems). We performed quantitative multiplex ELISA with the Beadlyte Universal Signaling Kit and protocol (Upstate Biotechnology). The antibodies used for bead conjugation were specific for VEGF (R&D Systems MAB293), GLUT-1 (Chemicon AB1340), VEGFR2 (Santa Cruz sc-504), phospho-Akt (Cell Signaling Technology 4056), and a-tubulin (Calbiochem CP06). We conjugated 10 mg of each antibody to carboxylated beads with the Bioplex Amine Coupling Kit and protocol (Bio-Rad Laboratories). We used the 8-plex Cell Signaling Kit (Upstate Biotechnology), containing eight different antibodies pre-conjugated to beads, to assess phospho-ERK1/2 abundance. We analyzed the samples with a Luminex 200 multiplex station. For equality from sample to sample and to limit margin of error, we isolated the same number of beads (500) for each protein in each experiment. We normalized data by dividing experimental values by control (a-tubulin) values.
Kinase arrays. Arrays containing 144 kinase substrate probes were provided by PamGene International B.V., and we used the arrays according to their protocols. Briefly, we incubated chips with cellular extracts in the presence of ATP and a fluorescently labeled antibody (PY20) to phospho-tyrosine for realtime detection of phospho-tyrosine residues with a PamStation 4. We used Bionavigator software (PamGene) for data analysis.
Proliferation and migration assay. We performed BrdU labeling for flow cytometry with a kit (Roche). We analyzed cells in a flow cytometer at an excitation of 488 nm. We assessed migration with the Innocyte Cell Migration Assay Kit (EMD Biosciences). Cell migration was assessed in 96-well transwell plates containing 8-mm pores in which the lower chambers contained 10% serum supplemented with 25 ng ml -1 VEGF. We stained migrated cells with Calcein-AM fluorescent dye. We assessed the excitation maximum (485 nm)/ emission maximum (520 nm) ratio with a fluorescent plate reader (BD FACSArray bioanalyzer, BD Biosciences).
